Soligenix Stock Forum

$Soligenix (SNGX.US)$ Benzinga· 2 mins ago
EXCLUSIVE: Soligenix Tells Benzinga Co. Initiates Confirmatory Phase III Trial Of HyBryte For The Treatment Of Cutaneous T-Cell Lymphoma

$Soligenix (SNGX.US)$
Soligenix Tells
Benzinga Co. Initiates Confirmatory
Phase III Trial Of HyBryte For The Treatment Ot Cutaneous T-Cell
Lymphoma
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
Monday, 16th December at 7:30 am
FLASH2 Study opens patient enrollment
PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on devel...

$Soligenix (SNGX.US)$ Soligenix Announced That Analysis Of The Post-treatment Data From The Open-label Study Comparing HyBryte (Synthetic Hypericin) To Valchlor (Mechlorethamine) Has Demonstrated Continued Improvement In HyBryte-treated Patients And Their Individual Lesions Even After Stopping Treatment

$Soligenix (SNGX.US)$ Reuters· just
Soligenix: 1 Of 5 Patients Receiving Valchlor Had to Be Withdrawn From Trial Due to a Clinically Significant Allergic Contact Dermatitis

$Soligenix (SNGX.US)$ Reuters
1 min ago
Hybryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

$Soligenix (SNGX.US)$
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
Monday, 2nd December at 7:30 am
Significant Efficacy against Plaque Lesions Also Demonstrated with HyBryte™
PRINCETON, N.J., Dec. 2, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that analysis of t...

$Soligenix (SNGX.US)$
19/11/2024 - 20:30
Phase 3 clinical study of HyBryte™ in CTCL initiating in 2024
PRINCETON, N.J., Nov. 19, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European M...

$Soligenix (SNGX.US)$ On Thursday, Soligenix Inc. (NASDAQ:SNGX) opened patient enrollment for its DUS-AUBD-01 Phase 2 study evaluating SGX945 (dusquetide) for Behçet's Disease, an inflammatory disorder of the blood vessels (vasculitis).
The company looks forward to completing enrollment and announcing study results in the first half of 2025.
The pilot clinical trial of SGX945 will be an open-label study that will enroll approximately 25 patients aged 18 years or older with mild to moderate...

$Soligenix (SNGX.US)$
Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
Soligenix (SNGX) has initiated patient enrollment for a Phase 2 clinical trial evaluating SGX945 (dusquetide) in treating Behçet's Disease.
The study received clearance from both FDA and Turkish authorities. The open-label trial will enroll approximately 25 patients with mild to moderate Behçet's Disease and active oral/genital ulcers.
Patients will receive twice-w...

$Soligenix (SNGX.US)$ fk me! im stuck with 8.36 🥲